ViRexx Medical Corp.

ViRexx Medical Corp.

November 10, 2005 15:56 ET

ViRexx Receives U.S. Patent for Occlusin'TM' Embolotherapy

EDMONTON, ALBERTA--(CCNMatthews - Nov. 10, 2005) - ViRexx Medical Corp. (TSX:VIR) a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy treatments for tumors, today announced that it has been granted U.S. Patent 6,960,352 entitled, "Compositions and Methods for Producing Vascular Occlusion Using a Solid-Phase Platelet Binding Agent". The patent broadly covers methods for treating vascularized tumors and hyperplastic tissues using solid-phase agents, such as particles, coils and stents, coated with von Willebrand factor.

"The Occlusin™ patent expands our proprietary T-ACT™ platform to cover embolotherapy applications designed to cut off the blood supply to tumors, thereby leading to tumor tissue starvation," commented Mr. Marc Canton, President and Chief Operating Officer of ViRexx. "Embolotherapy is a proven treatment for solid tumors. Our Occlusin™ 50 Injection product is a new innovative approach to embolotherapy using a natural biodegradable material to completely block blood flow to the target tissue. "

The Occlusin™ Injection product consists of albumin particles coated with von Willebrand factor. The particles are injected into the blood vessels of a target tumor and become lodged in the tumor vasculature thereby impeding the blood flow. Simultaneously, the von Willebrand factor acts to capture platelets circulating in the blood, which leads to rapid clot formation in the blood vessels feeding the tumor. The clot reduces the blood supply to the tumor, thus decreasing the supply of oxygen and nutrients, thereby causing tumor starvation.

Embolotherapy is used as a treatment for solid tumors for example malignant tumors, such as liver cancer, or benign tumors, such as uterine fibroids. The American Cancer Society reports that there are approximately 18,000 new cases of primary liver cancer diagnosed each year in the U.S. The five year U.S. survival rate for patients with all stages of liver cancer is 6%. Uterine fibroids impact over 40% of women over the age of 35 and have debilitating effects requiring therapy in over 2 million women in the U.S. every year.

ViRexx is currently conducting a Phase I trial of Occlusin™ 50 Injection for liver cancer. The trial is designed to examine the safety of the product when used as an embolizing agent as part of transcatheter arterial chemoembolization procedures. The study is being conducted under the direction of Dr. Morris Sherman at the Toronto General Hospital. Patient recruitment for the Phase I trial is expected to be completed in the fourth quarter of 2005.

ViRexx holds 46 issued patents and 141 pending patents dealing with the use of immunotherapy to treat cancer and viral infections and embolotherapy to treat tumors.

About ViRexx Medical Corp.

ViRexx is an Edmonton, Alberta based biotechnology company focused on the development of novel therapeutic products for the treatment of certain cancers and specified chronic viral infections. ViRexx's most advanced programs include drug candidates for the treatment of ovarian cancer, chronic hepatitis B & C and solid tumors.

ViRexx's lead product, OvaRex® MAb, a therapy for the treatment of late-stage ovarian cancer, is currently the subject of two Phase III clinical trials being funded by ViRexx's licensing partner Unither Pharmaceuticals, Inc., a subsidiary of United Therapeutics Corporation. For additional information about ViRexx, please see

This news release contains certain forward-looking statements that reflect the current views and/or expectations of the Company with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.


Contact Information